Everolimus plus immunotherapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests the combination of everolimus (a targeted pill) with a PD-1 immunotherapy drug for people with advanced colorectal cancer that has a specific gene change (PTEN mutation). The goal is to see if this two-drug approach works better than standard treatments for cancers that have stopped responding to chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your colorectal cancer is advanced or locally advanced and can't be fully removed with surgery.
- Your cancer has gotten worse or you couldn't tolerate at least one previous treatment that included a fluorouracil drug, irinotecan, and oxaliplatin (with or without Avastin). If your cancer started on the left side, it also must have included an anti-EGFR drug (like Erbitux).
- A test must show that your tumor has a PTEN gene mutation.
- You must be able to take care of yourself (ECOG 0-1) and have a life expectancy of at least 3 months.
- You have at least one measurable tumor (visible on scans).
- Your blood counts, kidney, and liver function must be within certain limits (your doctor will check).
- You cannot have had prior treatment with a PD-1 immunotherapy or an mTOR inhibitor.
- You cannot have an active autoimmune disease or a history of certain serious autoimmune conditions (like inflammatory bowel disease or lupus).
- You must be willing to use contraception if there is any chance of pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (rimegepant and a PD-1 immunotherapy) for people with colorectal cancer that has spread to the liver. It is for patients who have already tried standard chemotherapy without success.
This trial tests a combination of digoxin (a heart medication) with serplulimab (an immunotherapy) and chemotherapy as a first treatment for advanced colorectal cancer that is MSS (microsatellite stable). The goal is to see if this combination can help people whose cancer has stopped responding to previous treatments.
This trial tests the drug Everolimus for people with a specific type of advanced colorectal cancer (CDK12-deficient) that has progressed after standard treatments. The goal is to see if Everolimus can help shrink or control the cancer.
This Phase 3 study tests whether adding everolimus to chemotherapy (chosen by the treating team) can improve outcomes in advanced triple-negative breast cancer, specifically a subtype linked to PAM pathway changes. It may help patients who have not yet had treatment for advanced/metastatic disease.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests an immunotherapy drug (serplulimab) combined with targeted therapy, chemo, and radiation as a first treatment for people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if this combination can help control the cancer.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.